Clinical Report: Evaluation of Hepatitis C Care Cascade Outcomes Among Insured Adults
Overview
This cohort study evaluates hepatitis C care outcomes among insured adults in the U.S., revealing that 39.9% achieved viral clearance, while 35.7% initiated treatment.
Background
Hepatitis C virus (HCV) can lead to severe liver disease and mortality if untreated, but direct-acting antivirals (DAAs) can cure over 95% of cases.
Data Highlights
Outcome
Percentage
Viral Clearance
39.9%
Treatment Initiation
35.7%
Viral Clearance After Treatment Initiation
26.1%
Key Findings
Of 4,515,568 adults tested for HCV, 91,491 ever had HCV.
62.0% of those with HCV had initial infection.
38.3% of individuals with initial infection did not have follow-up RNA testing.
73.2% of those who initiated treatment had a subsequent HCV RNA-negative result.
21.3% of individuals without treatment initiation had evidence of viral clearance.
Clinical Implications
Healthcare providers should be aware of the limitations in data sources when evaluating treatment outcomes.
Conclusion
The findings highlight critical gaps in the hepatitis C care cascade.
